Quick Answer
Lipocine Inc. reported Cash and Equivalents of $5.21 million for fiscal year 2025.
Lipocine Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.21M | -16.1% |
| 2024 | $6.21M | +30.1% |
| 2023 | $4.77M | +51.6% |
| 2022 | $3.15M | +6.7% |
| 2021 | $2.95M | -84.6% |
| 2020 | $19.22M | +97.5% |
| 2019 | $9.73M | +20.4% |
| 2018 | $8.08M | +151.6% |
| 2017 | $3.21M | -42.3% |
| 2016 | $5.56M | -72.2% |
| 2015 | $20.01M | -27.7% |
| 2014 | $27.67M | -38.9% |
| 2013 | $45.26M | +741.8% |
| 2012 | $5.38M | -37.2% |
| 2011 | $8.57M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.90M | +4.2% | -35.5% |
| June 30, 2025 | $6.04M | +8.8% | +80.2% |
| March 31, 2025 | $3.35M | +8.9% | -45.9% |
| December 31, 2024 | $6.21M | +30.1% | +65.8% |
| September 30, 2024 | $3.74M | -8.1% | -32.6% |
| June 30, 2024 | $5.55M | +10.7% | +80.2% |
| March 31, 2024 | $3.08M | -35.4% | -35.4% |
| December 31, 2023 | $4.77M | +51.6% | +17.2% |
- Lipocine Inc. showed a decrease of -16.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Lipocine Inc.’s cash and equivalents has declined by 39.2% (from $8.57 million to $5.21 million).
- The most recent figure is from Lipocine Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: